ホーム>>Signaling Pathways>> PROTAC>> PROTAC Linker>>Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

カタログ番号GC62545

Tris[[2-(tert-ブトキシカルボニル)エトキシ]メチル]メチルアミンは、抗体薬物複合体 (ADC) の合成に使用される切断可能な PEG ADC リンカーです。アミノ-トリ-(t-ブトキシカルボニルエトキシメチル)-メタンも、PROTACの合成に使用できるPEG/アルキル/エーテルベースのPROTACリンカーです。

Products are for research use only. Not for human use. We do not sell to patients.

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine 化学構造

Cas No.: 175724-30-8

サイズ 価格 在庫数 個数
50 mg
$45.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is also a PEG/Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs[1].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

[1]. Kostiainen MA, et al. Optically degradable dendrons for temporary adhesion of proteins to DNA. Chemistry. 2010 Jun 18;16(23):6912-8.

レビュー

Review for Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.